

## **WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)**

### **Magnesium Sulfate 50%w/v Solution for Injection <sup>1</sup>**

Magnesium sulfate 50% w/v solution for injection, **10 mL**

Magnesium Sulfate 50% w/v Solution for Injection was submitted in 2017 by Martindale Pharma to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for the treatment of reproductive health conditions in women on 12 December 2017.

Information on the site(s) involved in the manufacture of the product and the API is available at the products listing information <https://extranet.who.int/prequal/medicines/rh077>

The “Procedure for prequalification of pharmaceutical products<sup>2</sup>” defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm), is based on the approval by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA, <https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency>) in line with the “Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities”<sup>3</sup>.

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant<sup>4</sup>.

Based on the submitted stability data WHO PQTm considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

---

<sup>1</sup> Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority’s responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

<sup>2</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2)

<sup>3</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2)

<sup>4</sup> [https://extranet.who.int/prequal/sites/default/files/document\\_files/48%20Stability%20data%20SRA%20FPPs\\_March2016\\_newtempl.pdf](https://extranet.who.int/prequal/sites/default/files/document_files/48%20Stability%20data%20SRA%20FPPs_March2016_newtempl.pdf)

- Do not store above 30°C.
- The shelf-life at this storage condition is 36 months

This WHOPAR refers to the information available at the approving stringent regulatory authority's website resulting from the assessment of the quality, efficacy and safety as well as steps taken after approval:

<https://products.mhra.gov.uk/search/?search=12064%2F0013&page=1> PL12064/0013

For details on the uses of this product, for relevant efficacy and safety information see the summary of product characteristics and the patient information leaflet as approved by MHRA

Summary of Product Characteristics

<https://mhraproducts4853.blob.core.windows.net/docs/b75958df7745da6ad3f42eb5579d3f1db2838529>

Patient Information Leaflet

<https://mhraproducts4853.blob.core.windows.net/docs/e1ad76eb570a520929541e6949ad173532d09572>

This WHOPAR for Magnesium Sulfate 50% w/v Solution for Injection is comprised of parts 2, 5 and 7.

Magnesium Sulfate 50% w/v Solution for Injection contains 50% magnesium sulfate solution. Its WHO recommended use is for treatment of reproductive health conditions in women.

#### Summary of Prequalification Status for Magnesium Sulfate 50%w/v Solution for Injection, (10mL)

	Initial Acceptance		Requalification	
	Date	Outcome	Date	Outcome
Status on PQ list	12 December 2017	listed	02 October 2024	listed
Dossier Evaluation	November 2017	MR	September 2024	requalified
PQ: prequalification MR: meets requirements				

The table represents the status of relevant completed activities only.